Drugs firm examined by regulator after ‘shocking’ safety breaches
The Health Products Regulatory Authority (HPRA) said it was concerned and was “following up with" drug maker Astellas
Ireland’s medicines regulator is assessing the possible implications for Ireland after the drugmaker Astellas was accused of “shocking” breaches of guidelines that “raised serious concerns with regard to patient safety” in Britain.
In a statement to this newspaper last week, the Health Products Regulatory Authority (HPRA) said it was concerned and was “following up with Astellas as regards any possible implications for the advertising and promotion of the company’s...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
Analysis: Variants and vaccines make projecting path of virus more complex
While the vaccine rollout should reduce the number of new Covid-19 cases, the increased transmissibility of the new variant mean progress in suppressing the virus has slowed
HSE’s latest private hospitals Covid deal estimated to cost €47 million a month
HSE considers ending surge capacity arrangements with private hospitals as number of Covid-19 hospitalisations falls
Key public health posts remain vacant
Frustrated doctors snub HSE jobs as talks over the long-promised consultant contract stall
Breakdown of HSE’s €1.6 billion war chest to fight Covid-19
The National Service Plan shows that €200m of the €1.6bn allocated to fighting the pandemic is to be spent on the rollout of vaccinations
